Literature DB >> 20660834

Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas.

Manuel Jorge Rodrigues, Johanna Wassermann, Laurence Albiges, Etienne Brain, Suzette Delaloge, Denise Stevens, Jean-Marc Guinebretière, Marie-Christine Mathieu, Youlia Kirova, Eugénie Guillot, Anne Vincent-Salomon, Paul H Cottu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20660834     DOI： 10.1200/JCO.2010.29.7952

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  15 in total

1.  Implications of HER2 amplification in small, node-negative breast cancers: do Asians differ?

Authors:  Fuh Yong Wong; Connie Siew Poh Yip; Eu Tiong Chua
Journal:  World J Surg       Date:  2012-02       Impact factor: 3.352

2.  Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice.

Authors:  S Antolín-Novoa; E Blanco-Campanario; A Antón; M I Gallegos-Sancho; R Pérez-Carrión; I Peláez; A Galán-Brotons; L de la Cruz-Merino; A Murías-Rosales
Journal:  Clin Transl Oncol       Date:  2015-06-24       Impact factor: 3.405

3.  High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers.

Authors:  Akiyo Horio; Takashi Fujita; Hironori Hayashi; Masaya Hattori; Naoto Kondou; Mai Yamada; Eri Adachi; Aya Ushio; Naomi Gondou; Aiko Sueta; Yasushi Yatabe; Hiroji Iwata
Journal:  Int J Clin Oncol       Date:  2011-06-18       Impact factor: 3.402

Review 4.  Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease.

Authors:  Rena Callahan; Sara Hurvitz
Journal:  Curr Opin Obstet Gynecol       Date:  2011-02       Impact factor: 1.927

5.  Trastuzumab for small HER-2+ breast cancer: small tumor, big decision.

Authors:  Roisin M Connolly; Aditya Bardia
Journal:  Oncologist       Date:  2012-04-04

6.  Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study.

Authors:  Stefania Gori; Matteo Clavarezza; Salvatore Siena; Jennifer Foglietta; Emiliana Tarenzi; Monica Giordano; Annamaria Molino; Claudio Graiff; Vittorio Fusco; Oscar Alabiso; Editta Baldini; Teresa Gamucci; Giuseppe Altavilla; Davide Dondi; Marco Venturini
Journal:  BMC Cancer       Date:  2012-04-30       Impact factor: 4.430

7.  Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis.

Authors:  T Gamucci; A Vaccaro; F Ciancola; L Pizzuti; I Sperduti; L Moscetti; F Longo; M A Fabbri; M A Giampaolo; L Mentuccia; L Di Lauro; P Vici
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-15       Impact factor: 4.553

8.  Exploring the use and impact of adjuvant trastuzumab for HER2-positive breast cancer patients in a large UK cancer network. Do the results of international clinical trials translate into a similar benefit for patients in South East Wales?

Authors:  R M Webster; J Abraham; N Palaniappan; A Caley; B Jasani; P Barrett-Lee
Journal:  Br J Cancer       Date:  2011-11-22       Impact factor: 7.640

9.  For or against adjuvant trastuzumab for pT1a-bN0M0 breast cancer patients with HER2-positive tumors: a meta-analysis of published literatures.

Authors:  Qiong Zhou; Wenjin Yin; Yueyao Du; Jinsong Lu
Journal:  PLoS One       Date:  2014-01-02       Impact factor: 3.240

10.  HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort.

Authors:  Philippe Rouanet; Pascal Roger; Emilie Rousseau; Severine Thibault; Gilles Romieu; Andre Mathieu; Jacques Cretin; Gilbert Barneon; Mireille Granier; Aurelie Maran-Gonzalez; Jean P Daures; Florence Boissiere; Frederic Bibeau
Journal:  Cancer Med       Date:  2014-01-10       Impact factor: 4.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.